West Nile virus in blood: Stability, distribution, and susceptibility to PEN110 inactivation

Transfusion

Volumn 43, Issue 8, 2003, Pages 1029-1037

  Mather, Thomas ^b   Takeda, Tsutomu ^b   Tassello, Jodie ^b   Ohagen, Asa ^b   Serebryanik, Diana ^b   Kramer, Ed ^b   Brown, Fred ^b   Tesh, Robert ^b   Alford, Bernadette ^b   Chapman, John ^b   Lazo, Aris ^a  

^a VI Technologies Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PEN110; REAGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ARTICLE; BIOTECHNOLOGY; BLOOD BANK; BLOOD TRANSFUSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ERYTHROCYTE; HAMSTER; HUMAN; HUMAN CELL; LEUKOCYTE; NONHUMAN; PROCESS TECHNOLOGY; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS SURVIVAL;

ANIMALS; ANTIVIRAL AGENTS; BLOOD; BLOOD BANKS; BLOOD PRESERVATION; CERCOPITHECUS AETHIOPS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; HUMANS; KINETICS; LEUKAPHERESIS; POLYAMINES; VERO CELLS; VIRUS INACTIVATION; VIRUS REPLICATION; WEST NILE FEVER; WEST NILE VIRUS;

EID: 0041428185     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00464.x     Document Type: Article

References (22)

1. Campbell G, Marfin A, Lanciotti R, et al. West Nile virus. Lancet Infect Dis 2002;2:519-29.
2. Brinton M. The molecular biology of West Nile virus: a new invader of the western hemisphere. Annu Rev Microbiol 2002;56:371-402.
3. Petersen L, Marfin A. West Nile virus: a primer for the clinician. Ann Intern Med 2002;137:173-9.
4. West Nile virus activity - United States 2001. MMWR Morb Mortal Wkly Rep 2002;51:497-501.
5. Investigations of West Nile virus infections in recipients of blood transfusions. MMWR Morb Mortal Wkly Rep 2002;51:973-4.
6. Lazo A, Tassello J, Jayarama V, et al. Broad-spectrum virus reduction in red cell concentrates using INACTINE™ PEN110 chemistry. Vox Sang 2002;83:313-23.
7. Ohagen A, Gibaja V, Aytay S, et al. Inactivation HIV in blood. Transfusion 2002;42:1308-17.
8. Zavizion B, Serebryanik D, Serebryanik I, et al. Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process. Transfusion 2003;43:135-42.
9. Purmal A, Valeri CR, Dzik W, et al. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies. Transfusion 2002;42:139-45.
10. Steele KE, Linn MJ, Schoepp RJ, et al. Pathology of fatal West Nile virus infections in native and exotic birds during the 1999 outbreak in New York City, New York. Vet Pathol 2000;37:208-24.
11. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (Internet). CPMP/BWP/268/95. London: EMEA; 1996 Feb 29. Available from: http://www.emea.eu.int/htms/human/bwp/bwpfin.htm
12. Karber J. Beitrag zur kollectiven Behandlung pharmacologische Reihenversuche. Arch Exp Path Pharmak 1931;162:480-3.
13. Ng ML, Tan SH, Chu JJH. Transport and budding at two distinct sites of visible nucleocapsids of West Nile (Sarafend) virus. J Med Virol 2001;65:758-64.
14. Xiao S, Guzman H, Zhang H et al. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis 2001;7:714-21.
15. Deubel V, Fiette L, Gounon P, et al. Variations in biological features of West Nile viruses. Ann N Y Acad Sci 2001;951:195-206.
16. Peiris JS, Porterfield JS. Antibody-mediated enhancement of flavivirus replication in macrophage-like cell lines. Nature 1979;282:509-11.
17. Chen YC, Wang SY. Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide. J Virol 2002;76:9877-87.
18. Hasegawa H, Satake Y, Kobayashi Y. Effect of cytokines on Japanese encephalitis virus production by human monocytes. Microbiol Immunol 1990;34:459-66.
19. Diamond MS, Edgil D, Roberts TG, Lu B, Harris E. Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol 2000;74:7814-23.
20. Söderberg-Nauclér C, Fish K, Nelson J. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997;91:119-26.
21. Ibanez CE, Schrier R, Ghazal P, et al. Human cytomegalovirus productively infects primary differentiated macrophages. J Virol 1991;65:6581-8.
22. Gendelman HE, Orenstein JM, Martin MA, et al. Efficient isolation and propagation of human immunodeficiency virus on rCSF-1 treated monocytes. J Exp Med 1988;167:1428-41.